Elizabeth A Suarez, Brian T Bateman, Loreen Straub, Sonia Hernández-Díaz, Hendrée E Jones, Kathryn J Gray, Hilary S Connery, Jonathan M Davis, Barry Lester, Mishka Terplan, Yanmin Zhu, Seanna M Vine, Helen Mogun, Krista F Huybrechts
IMPORTANCE: Use of buprenorphine or methadone to treat opioid use disorder is recommended in pregnancy; however, their teratogenic potential is largely unknown. OBJECTIVE: To compare the risk of congenital malformations following in utero exposure to buprenorphine vs methadone. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study used health care utilization data from publicly insured Medicaid beneficiaries in the US from 2000 to 2018...
January 22, 2024: JAMA Internal Medicine